Racecadotril: Clinical Evidence, Safety Profile, and Guideline Recommendations

Mechanistic Distinction from Loperamide

• Racecadotril does not reduce intestinal motility or prolong gastrointestinal transit time, unlike loperamide, which acts as a μ‑opioid receptor agonist to slow transit. This difference suggests a lower risk of bacterial overgrowth and toxic megacolon in inflammatory or invasive diarrheal conditions. 1

Safety and Tolerability Advantages

• Because it does not affect gut motility, racecadotril is associated with significantly less rebound constipation after diarrhea resolution compared with loperamide. [2][3]
• The peripheral action of racecadotril (its active metabolite does not cross the blood‑brain barrier) eliminates concerns about central nervous system side effects such as sedation or addiction. [2][3]

Guideline Recommendations

• The European Society for Medical Oncology (ESMO) assigns Level III evidence with a Grade A recommendation for using racecadotril interchangeably with loperamide to treat Grade 1 immunotherapy‑induced diarrhea, highlighting its antisecretory mechanism as a distinguishing benefit. 4

Prophylactic Use in Chemotherapy‑Induced Diarrhea

• A randomized trial evaluating prophylactic racecadotril (100 mg three times daily for 15 days) in patients receiving irinotecan‑based chemotherapy showed no reduction in the incidence of diarrhea compared with placebo. This finding indicates that routine prophylaxis with racecadotril is not supported. [5][6]

Comparative Indications with Loperamide

• Racecadotril lacks specific evaluation and guideline endorsement for the treatment of travelers’ diarrhea, whereas loperamide is strongly supported by guidelines and holds an FDA‑approved indication for this condition. [1][2]